DDX39B (BAT1), TNF and IL6 gene polymorphisms and association with clinical outcomes of patients with Plasmodium vivax malaria

Table 1 Characteristics of the second series of participants with complicated vivax malaria: Amazonas, Brazil

			Clinical presentation at admission
Patient no.	Gender	Age (years)	Major manifestation	Secondary manifestation	Previous treatment	Parasitaemia	Disease duration (days)	Haemoblogin (g/dL)	Total bilirubin (μmol/L)
1	M	59	hyperbilirubinaemia		No	6,222	7	16.9	403.56
2	F	38	hyperlactemia		Yes	0	10	10.9	30.78
3	M	31	hyperbilirubinaemia		No	3,298	10	11.0	54.72
4	F	37	hyperbilirubinaemia		No	67,467	7	8.9	51.30
5	M	18	hyperbilirubinaemia		No	1,848	4	13.5	165.87
6	M	45	severe anaemia	hyperbilirubinaemia	No	243	10	6.5	138.51
7	F	40	severe anaemia		No	33,553	10	7.0	27.36
8	M	66	convulsion		Yes	185	14	13.0	*
9	M	17	hyperbilirubinaemia		No	226	6	11.9	53.01
10	M	31	hyperbilirubinaemia		No	5,937	15	13.5	165.87
11	M	1	severe anaemia		No	38,712	9	5.0	8.55
12	M	26	hyperbilirubinaemia		No	128	2	10.6	61.56
13	F	4 months	convulsion	prostration	No	108,033	7	11.7	*
14	M	19	severe anaemia		No	0	17	6.5	15.39
15	M	50	respiratory failure		No	310	5	10.1	8.55
16	F	35	severe anaemia	hyperbilirubinaemia	No	34,673	1	4.8	138.51
17	F	41	respiratory failure		No	24,815	8	9.9	39.33
18	F	18	hyperbilirubinaemia		No	670	5	11.7	61.56
19	M	44	severe anaemia		Yes	0	7	6.9	13.68
20	F	23	severe anaemia		Yes	264	8	6.4	6.84
21	M	5	prostration		No	291	15	8.2	6.84
22	M	21	hyperbilirubinaemia		Yes	832	7	9.7	102.6
23	M	12	respiratory failure		Yes	0	6	7.8	15.39
24	F	74	respiratory failure		No	325	5	11.7	29.07
25	M	37	respiratory failure		Yes	0	10	7.1	17.10
26	F	26	hyperbilirubinaemia		No	254	9	11.3	140.22
27	M	53	hyperbilirubinaemia		No	45,833	6	11.8	59.85
28	F	36	hyperbilirubinaemia		No	0	3	7.9	85.50
29	F	15	severe anaemia		Yes	8,894	8	6.9	11.97
30	M	22	hyperbilirubinaemia		No	3,054	7	15.1	73.53
31	M	25	hyperbilirubinaemia		Yes	27,954	3	15.0	138.51

Severe anaemia was defined as haemoglobin levels below 7 g/dL for adults and below 5 g/dL for children and hyperbilirubinaemia by serum total bilirubins >51.3 μmol/L. Respiratory failure was defined as tachypnea, shortness of breath, mental confusion clinical signs of hypoxaemia (central and/or peripheral cyanosis). Previous treatment indicates participants who already started malaria therapy before the blood sample collection. *Total bilirubin was not measured in these individuals.

ISSN: 1475-2875